Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,559,190
  • Shares Outstanding, K 61,631
  • Annual Sales, $ 264,730 K
  • Annual Income, $ -128,080 K
  • 60-Month Beta 1.97
  • Price/Sales 10.88
  • Price/Cash Flow N/A
  • Price/Book 5.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.53
  • Number of Estimates 4
  • High Estimate -0.22
  • Low Estimate -0.78
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -15.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.80 +23.40%
on 02/06/20
58.44 -1.19%
on 02/12/20
+7.69 (+15.36%)
since 01/14/20
3-Month
42.03 +37.40%
on 11/21/19
58.44 -1.19%
on 02/12/20
+15.03 (+35.18%)
since 11/14/19
52-Week
29.06 +98.73%
on 02/15/19
58.44 -1.19%
on 02/12/20
+28.70 (+98.80%)
since 02/14/19

Most Recent Stories

More News
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year-end 2019 financial results and provide an update on the...

PTCT : 57.75 (+1.73%)
Ptc Therapeutics Has Returned 49.2% Since SmarTrend Recommendation (PTCT)

SmarTrend identified an Uptrend for Ptc Therapeutics (NASDAQ:PTCT) on October 23rd, 2019 at $37.80. In approximately 4 months, Ptc Therapeutics has returned 49.17% as of today's recent price of $56.38....

PTCT : 57.75 (+1.73%)
Look for Shares of Ptc Therapeutics to Potentially Pullback after Yesterday's 2.10% Rise

Ptc Therapeutics (NASDAQ:PTCT) traded in a range yesterday that spanned from a low of $54.99 to a high of $56.57. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high...

PTCT : 57.75 (+1.73%)
SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that positive 1 year clinical data from Part 2 of the pivotal SUNFISH study evaluating risdiplam in people aged 2-25 years with nonambulatory type...

PTCT : 57.75 (+1.73%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 29, 2020 it approved non-statutory stock options to purchase an aggregate of 182,150 shares of its common stock to 57 new employees....

PTCT : 57.75 (+1.73%)
PTC Therapeutics to Host A Conference Call to Review Part 2 of the SUNFISH Clinical Trial Data at the SMA Europe Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will host a conference call on Thursday, February 6, 2020, at 8:00 am ET highlighting data on risdiplam in type 2/3 spinal muscular...

PTCT : 57.75 (+1.73%)
PTC Therapeutics Announces First Publication of Real-World Data Showing Translarnaä (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy

PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced real-world data showing that boys with nonsense mutation Duchenne muscular dystrophy treated with Translarna(TM) (ataluren) and standard of care (SoC),...

PTCT : 57.75 (+1.73%)
MRI Interventions, Inc. Closes $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management

MRI Interventions, Inc. (Nasdaq: MRIC) (the "Company"), a leading platform neurosurgery company, closed its previously announced $17.5 million strategic investment from PTC Therapeutics, Inc. ("PTC") and...

MRICD : 7.0500 (-2.08%)
PTCT : 57.75 (+1.73%)
MRIC : 5.14 (-0.48%)
Shares of PTCT Up 41.6% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Ptc Therapeutics (NASDAQ:PTCT) on October 23rd, 2019 at $37.80. In approximately 3 months, Ptc Therapeutics has returned 41.58% as of today's recent price of $53.51....

PTCT : 57.75 (+1.73%)
Roche's Risdiplam Meets Primary Endpoint in Infants Study

Roche's (RHHBY) risdiplam meets primary endpoint in FIREFISH study in infants with type 1 spinal muscular atrophy.

RHHBY : 43.3900 (-0.66%)
NVS : 97.63 (-0.14%)
BIIB : 333.00 (-0.37%)
PTCT : 57.75 (+1.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade PTCT with:

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

2nd Resistance Point 59.42
1st Resistance Point 58.58
Last Price 57.75
1st Support Level 56.77
2nd Support Level 55.80

See More

52-Week High 58.44
Last Price 57.75
Fibonacci 61.8% 47.22
Fibonacci 50% 43.75
Fibonacci 38.2% 40.29
52-Week Low 29.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar